{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:40:08Z","timestamp":1791261608219,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:43:57Z","timestamp":1772628237000},"page":"391-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Eliabe S.","family":"Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cld.2026.01.004_bib1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000325","article-title":"Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: data from a phase 3 study","volume":"8","author":"Sanyal","year":"2024","journal-title":"Hepatol Commun"},{"issue":"10","key":"10.1016\/j.cld.2026.01.004_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.cld.2026.01.004_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2026.01.004_bib7","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.cld.2026.01.004_bib8","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2026.01.004_bib9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.01.004_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.004_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001509","article-title":"Non-invasive tests: establishing efficacy for metabolic dysfunction-associated steatohepatitis beyond the biopsy-current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration","author":"Anania","year":"2025","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.cld.2026.01.004_bib12","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2026.01.004_bib13","article-title":"Vitamin E (300 mg) in the treatment of MASH: a multi-center, randomized, double-blind, placebo-controlled study","volume":"6","author":"Song","year":"2025","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.cld.2026.01.004_bib14","first-page":"3924","article-title":"Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis","volume":"8","author":"Xu","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"7\u20138","key":"10.1016\/j.cld.2026.01.004_bib15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","article-title":"Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"31","author":"Sato","year":"2015","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.cld.2026.01.004_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.cld.2026.01.004_bib17","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1001\/jama.2012.14641","article-title":"Multivitamins in the prevention of cancer in men: the physicians' health study II randomized controlled trial","volume":"308","author":"Gaziano","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.cld.2026.01.004_bib18","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1158\/1055-9965.EPI-09-0013","article-title":"Dietary supplement use and prostate cancer risk in the carotene and retinol efficacy trial","volume":"18","author":"Neuhouser","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cld.2026.01.004_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","article-title":"Pharmacotherapy of type 2 diabetes: an update","volume":"78","author":"Upadhyay","year":"2018","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib20","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.cld.2026.01.004_bib21","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2026.01.004_bib22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/gutjnl-2017-313958","article-title":"Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus","volume":"67","author":"Cusi","year":"2018","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.cld.2026.01.004_bib23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.cld.2026.01.004_bib25","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.cld.2026.01.004_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11892-013-0378-8","article-title":"The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus","volume":"13","author":"Yau","year":"2013","journal-title":"Curr Diab Rep"},{"issue":"22","key":"10.1016\/j.cld.2026.01.004_bib27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cld.2026.01.004_bib28","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"11\u201312","key":"10.1016\/j.cld.2026.01.004_bib29","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: Baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"21","key":"10.1016\/j.cld.2026.01.004_bib30","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/HEP.0000000000001084","article-title":"Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis","volume":"81","author":"Younossi","year":"2025","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2026.01.004_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: october 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.004_bib35","doi-asserted-by":"crossref","unstructured":"Noureddin M KK, Clawson A. Once-monthly efimosfermin alfa (BOS-580) in metabolic dysfunction-associated steatohepatitis with F2\/F3 fibrosis: results from a 24 week, randomized, doubleblind, placebo-controlled, phase 2 trial AASLD abstract 5017. Presented at: The Liver Meeting; November 15-19, 2024; San Diego, CA.","DOI":"10.1016\/S0016-5085(25)04659-1"},{"key":"10.1016\/j.cld.2026.01.004_bib36","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0168-8278(25)00311-3","article-title":"LBO-002 treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis","volume":"82","author":"Alkhouri","year":"2025","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2026.01.004_bib37","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2026.01.004_bib38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2026.01.004_bib39","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jama.2024.0318","article-title":"Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes","volume":"331","author":"Courcoulas","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.cld.2026.01.004_bib40","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1007\/s11695-017-2866-4","article-title":"The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis","volume":"27","author":"Sheng","year":"2017","journal-title":"Obes Surg"},{"issue":"3","key":"10.1016\/j.cld.2026.01.004_bib41","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"9","key":"10.1016\/j.cld.2026.01.004_bib42","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2026.01.004_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly Obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib44","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.cld.2026.01.004_bib45","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"10390","key":"10.1016\/j.cld.2026.01.004_bib46","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cld.2026.01.004_bib47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","article-title":"Safety of metabolic and bariatric surgery in Obese patients with liver cirrhosis: a systematic review and meta-analysis","volume":"17","author":"Agarwal","year":"2021","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"10.1016\/j.cld.2026.01.004_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11695-018-3562-8","article-title":"Outcomes of bariatric surgery in patients with cirrhosis","volume":"29","author":"Minambres","year":"2019","journal-title":"Obes Surg"},{"issue":"Supplement_1","key":"10.1016\/j.cld.2026.01.004_bib49","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.cld.2026.01.004_bib50","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib51","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1210\/endo.133.4.8404634","article-title":"Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor","volume":"133","author":"Dillon","year":"1993","journal-title":"Endocrinology"},{"issue":"6220","key":"10.1016\/j.cld.2026.01.004_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.cld.2026.01.004_bib54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/apt.18042","article-title":"Randomised clinical trial: design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures","volume":"60","author":"Vuppalanchi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2026.01.004_bib57","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.004_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110779","article-title":"Perspectives in weight control in diabetes - survodutide","volume":"207","author":"Klein","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib59","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13098-024-01501-x","article-title":"Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials","volume":"16","author":"Wan","year":"2024","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/oby.24184","article-title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)","volume":"33","author":"Wharton","year":"2025","journal-title":"Obesity"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cld.2026.01.004_bib62","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and efficacy of novel incretin co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib64","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-Gomez","year":"2023","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.cld.2026.01.004_bib65","first-page":"1629","article-title":"Triple-hormone-receptor agonist retatrutide for obesity","volume":"389","author":"Elfeki","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2026.01.004_bib66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-024-03646-0","article-title":"A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity","volume":"80","author":"Kaur","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cld.2026.01.004_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2024.100321","article-title":"Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Pasqualotto","year":"2024","journal-title":"Metabol Open"},{"key":"10.1016\/j.cld.2026.01.004_bib68","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000793","article-title":"The first triple agonist for antiobesity: retatrutide","author":"Tetelbaun","year":"2024","journal-title":"Cardiol Rev"},{"issue":"1\u20132","key":"10.1016\/j.cld.2026.01.004_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/17512433.2025.2450254","article-title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","volume":"18","author":"Tewari","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.cld.2026.01.004_bib70","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.cld.2026.01.004_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107176","article-title":"A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - study design and rationale of HM-TRIA-201 study","volume":"130","author":"Abdelmalek","year":"2023","journal-title":"Contemp Clin Trials"},{"issue":"11","key":"10.1016\/j.cld.2026.01.004_bib72","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.cld.2026.01.004_bib73","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.004_bib74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1124\/jpet.123.001618","article-title":"The novel GlycoPEGylated FGF21 analog pegozafermin activates human FGF receptors and improves metabolic and liver outcomes in diabetic monkeys and healthy human volunteers","volume":"387","author":"Rosenstock","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.cld.2026.01.004_bib75","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cld.2026.01.004_bib76","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"24","key":"10.1016\/j.cld.2026.01.004_bib77","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"issue":"12 Suppl 11","key":"10.1016\/j.cld.2026.01.004_bib78","first-page":"15","article-title":"Once-monthly efimosfermin alfa (BOS-580) in metabolic dysfunction-associated steatohepatitis with F2\/F3 fibrosis: results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"20","year":"2024","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.004_bib79","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.gastha.2024.05.006","article-title":"Lanifibranor reduces inflammation and improves dyslipidemia in lysosomal acid lipase-deficient mice","volume":"3","author":"Bradic","year":"2024","journal-title":"Gastro Hep Adv"},{"issue":"5","key":"10.1016\/j.cld.2026.01.004_bib80","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.cld.2026.01.004_bib81","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2026.01.004_bib82","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/hep4.1723","article-title":"Deuterium-stabilized (R)-pioglitazone (PXL065) is responsible for pioglitazone efficacy in NASH yet exhibits little to no PPARgamma activity","volume":"5","author":"Jacques","year":"2021","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.cld.2026.01.004_bib83","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2026.01.004_bib84","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1111\/dom.16506","article-title":"Effect of saroglitazar on glycaemic parameters: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Simental-Mendia","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.cld.2026.01.004_bib85","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a dual PPAR alpha\/gamma agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis","volume":"21","author":"Siddiqui","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.01.004_bib86","article-title":"An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra","year":"2020","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.cld.2026.01.004_bib87","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2026.01.004_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.101398","article-title":"A prospective randomised comparative four-arm intervention study of efficacy and safety of saroglitazar and vitamin E in patients with non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-SVIN TRIAL","volume":"14","author":"Mir","year":"2024","journal-title":"J Clin Exp Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2026.01.004_bib89","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.004_bib90","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1453","article-title":"Icosabutate exerts beneficial effects upon insulin sensitivity, hepatic inflammation, lipotoxicity, and fibrosis in mice","volume":"4","author":"van den Hoek","year":"2020","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib91","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000445047","article-title":"Icosabutate, a structurally engineered fatty acid, improves the cardiovascular risk profile in statin-treated patients with residual hypertriglyceridemia","volume":"135","author":"Kastelein","year":"2016","journal-title":"Cardiology"},{"issue":"1","key":"10.1016\/j.cld.2026.01.004_bib92","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2015.10.012","article-title":"Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week clinical trial","volume":"10","author":"Bays","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.004_bib93","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2025.01.032","article-title":"A phase IIb randomised-controlled trial of the FFAR1\/FFAR4 agonist icosabutate in MASH","volume":"83","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.01.004_bib94","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.004_bib95","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2026.01.004_bib96","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2026.01.004_bib97","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/HEP.0000000000000860","article-title":"MASH clinical trials and drugs pipeline: an impending tsunami","volume":"82","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.cld.2026.01.004_bib98","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186425","article-title":"Therapeutic Horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J Clin Investig"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:57:25Z","timestamp":1778878645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326126000048"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}